Cytori Therapeutics (CYTX) Misses Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities rebound to close higher as surging Treasury yields recede
- Fed’s Jefferson sees no urgency for another rate increase
- Oil jumps 4% on reports China halts fuel exports, US troops head to Middle East
- Amazon and these four U.S. stocks are latest additions to Goldman’s flagship list
- Anthropic targets mid-November for public debut - report
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- Twilio, Vylor set to join S&P 500 as index reshuffles members
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
Maxim Group Downgrades Cytori Therapeutics, Inc. (CYTX) to Hold
August 15, 2018 7:40 AM EDTMaxim Group analyst Jason McCarthy downgraded Cytori Therapeutics, Inc. (NASDAQ: CYTX) from Buy to Hold and removes their price target.
McCarthy said their fundamental view around the company's key programs of 0918 (liposomal doxorubicin) and cell therapy (scleroderma, stress urinary incontinence) are unchanged, but... More
Cytori Therapeutics, Inc. (CYTX) PT Lowered to $5 at H.C. Wainwright on Rising Share Count
August 15, 2018 7:12 AM EDTH.C. Wainwright analyst Jason Kolbert lowered the price target on Cytori Therapeutics, Inc. (NASDAQ: CYTX) to $5.00 (from $6.00) while maintaining a Buy rating.
Kolbert notes while catalysts lay ahead they are lowering the price target on a rising share... More
